Protocol Design

Study examines how many registered clinical trials with published protocols are also publishing their results.

Study findings elevate the need to optimize protocol amendment experience.

While steady progress has been made in recent years, CROs and sponsors still have decisions to make on which solutions are best for them.

It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.

Webinar Date/Time: Tue, Sep 19, 2023 11:00 AM EDT

Webinar Date/Time: Thursday, September 7th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Recent study results highlight need for new metrics in ECOG scoring to mitigate variability.

In this Q&A, Santuccione Chadha speaks on the lack of sex- and gender-based analysis in clinical trial results.

These devices can help researchers identify data points that are not immediately available to researchers.

Webinar Date/Time: Wednesday, March 29, 2023 at 11am ET |10 am CT | 8am PT

Webinar Date/Time: Wednesday, March 22nd, 2023 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Buy-in from industry stakeholders pivotal to ensure bright future for the decentralized approach.

Webinar Date/Time: Tue, Feb 21, 2023 11:00 AM EST

Tufts CSDD study addresses barriers in recruitment.

Data from past clinical trials has provided researchers with a good starting point to create more ECAs.

Pandemic has brought new sense of awareness to respiratory diseases and clinops.

Natural language processing can help simplify protocols of the past, as evidenced by a recent Novartis initiative.

Study uncovers pre-pandemic deviation levels.

Addressing sources of tension on differentiating types of data.

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

A look at the prevalence of placebo response in clinical trials and how advanced solutions can mitigate the risk it poses to drug development.

Implementing new strategies with the use of patient-reported outcomes.

Insights from studies on advisory boards and participation burden.